Wharton's Jelly

Overview

Minimally processed UCT Wharton's Jelly containing intact extracellular matrix, MSCs, bioactive proteins, and growth factors — the most complete biological tissue preparation in the Akira Biotech portfolio

Related: Stem Cells Overview

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Wharton's Jelly (WJ) is the native gelatinous matrix of the umbilical cord, containing UCT-MSCs embedded in a rich extracellular matrix of hyaluronic acid, collagen I/III/IV/VI, fibronectin, laminin, proteoglycans, and endogenous growth factors. Minimally processed Wharton's Jelly preparations preserve the complete tissue niche — including cell-matrix interactions, matrix-bound growth factors, and the full structural ECM scaffold. This makes WJ particularly effective for applications requiring scaffold-mediated tissue integration (orthopedic, wound healing, surgical augmentation) where the matrix architecture provides additional structural support and growth factor reservoirs beyond what isolated cells or exosomes can deliver.

How Whole-Tissue Wharton's Jelly Works

Whole-tissue Wharton's Jelly is processed by gentle rinsing, mechanical trimming, and cryopreservation — without decellularization, but also without cell culture or expansion. Independent compositional analyses of minimally-manipulated WJ allografts have found low total cell counts with highly variable, often minimal post-thaw viability, so the product is best understood as an acellular-dominant, matrix-driven biologic rather than a cell-therapy product — a distinct category from Akira's cultured, expanded UCT-WJ-MSC injection product. In order of evidentiary support:

• Structural ECM Scaffold: The native architecture of collagens (I, III, IV, VI, and others), fibronectin, laminin, and hyaluronic acid is preserved intact, providing mechanical cushioning, a substrate for host cell adhesion and infiltration, and structural continuity at sites of tissue defect — the best-supported and most homologous use of the tissue.
• Matrix-Bound Growth Factor Depot: Growth factors and cytokines (TGF-β, VEGF, FGF, HGF) are physically retained within the ECM rather than delivered as a bolus, providing a localized, slow-release depot.
• Hydration & Lubrication: Hyaluronic acid and proteoglycans (versican, aggrecan) contribute to tissue hydration and joint lubrication.
• Adjunct Resident-Cell Contribution: Trace resident cells (including any surviving native MSCs) may contribute limited paracrine signaling, but given the low viable-cell content documented in independent testing, this is a minor, not primary, driver of clinical effect.

Key Components

Potential Applications

• Orthopedic — osteoarthritis, cartilage defects, tendon/ligament repair
• Wound Healing — chronic wounds, burns (scaffold cells)
• Anti-Inflammatory — joint injections, systemic use
• Dental / Oral Surgery — alveolar bone repair, guided tissue regeneration
• Aesthetic / Anti-Aging — facial rejuvenation injections, skin quality
• Spinal Applications — disc augmentation, facet joint support

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Clinical Evidence

Evidence specific to minimally-manipulated whole-tissue WJ allografts (as opposed to cultured/expanded MSC injections, a separate product category) is limited to small case series and retrospective cohorts. Applications without direct trial evidence below — wound healing, facial rejuvenation, disc augmentation — are extrapolated from the tissue's known composition and from evidence for adjacent product categories (cultured MSC therapy, MSC-derived exosomes), not from direct trials of this whole-tissue preparation.